In cerebrovascular diseases

Kontos, H. (1989). Oxygen radicals in cerebral ischemia. In Cerebrovascular Diseases (eds. M.D. Ginsberg and W.D. Dietrich) pp. 365-371. Raven Press, New York. [Pg.81]

In cerebrovascular diseases, the phospholipase-A2-related signaling triggered by ischemia-reperfusion may be part of a delicate balance between neuroprotection and neuronal cell death 584... [Pg.575]

Celecoxib, a non-steroidal anti-inflammatory drug, is a cyclo-oxygenase-2 selective inhibitor that is as effective as diclofenac and naproxen. It should be used for the shortest period required to control symptoms. Use is associated v/ith an increased risk of thrombotic events and the cyclo-oxygenase-2 selective inhibitors are contraindicated in cerebrovascular disease. Mobic is the proprietary preparation of meloxicam. [Pg.29]

DL Gordan, RJ Linhardt, HP Adams. Low-molecular-weight heparin and heparinoids in cerebrovascular disease. Clin Neuropharmacol 13 522-543, 1990. [Pg.310]

Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA. 2004 292 1867-1874. [Pg.319]

Snider BJ, Gottron FJ, Choi DW (1999) Apoptosis and necrosis in cerebrovascular disease. Ann NY Acad Sci 893 243-253... [Pg.147]

Busto R. and Ginsberg M. D. (1998) The influence of altered brain temperature in cerebral ischemia. In Cerebrovascular Disease Pathophysiology, Diagnosis and Management (Ginsberg M. D. and Bogousslavsky, J., eds.), Blackwell Science, Malden, pp. 287-307. [Pg.31]

Langley MS, Sorkin EM (1989) Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 37 669-99 Review... [Pg.640]

Chan, P.H., Fishman, R.A. (1985). Free fatty acids, oxygen Iree radicals and membrane alterations in brain ischemia and injury. In Cerebrovascular Diseases (F. Plum, W. Pulsinelli, eds), pp. 161-7. Raven Press, New York. [Pg.266]

McCarron MO, Muir KW, Weir CJ et al 1998 The apolipoprotein E s4 allele and outcome in cerebrovascular disease. Stroke 29 1882-1887... [Pg.57]

Carusone LM, Srinivasan J, Gitelman DR, Mesulam MM, Parrish TB. Hemodynamic response changes in cerebrovascular disease implications for functional MR imaging. AJNR Am J Neuroradiol 2002 23 1222-8. [Pg.177]

Heiss W-D, Herholz K, Podreka I, Neubauer I, Pietrzyk U (1990) Comparison of " Tc-HM-PAO SPECT with F-fluoromethane PET in cerebrovascular disease. J Cereb Blood Flow Metab 10 687-697... [Pg.258]

King A, Markus HS Doppler embolic signals in cerebrovascular disease and prediction of stroke risk, a systematic review and meta-analysis. Stroke 2009 40 pp. 3711-3717. [Pg.40]

Lee, T.Y., Scientific basis and validation, in Multidetector computed tomography in cerebrovascular disease, K.A.E. MUes, Eastwood J.D., Konig M., Editors. 2007, Abingdon Informa Healthcare, p. 13-27. [Pg.117]

Sette G, Baron JC, Mazoyer B, Levasseur M, Pappata S, Crouzel C. Local brain haemodynamics and oxygen metabolism in cerebrovascular disease. Positron emission tomography. Brain. 1989 112 931-951... [Pg.194]

Hossmann, K.A. (1998) Thresholds of Ischemic Injury. In Cerebrovascular Disease Pathophysiology, Diagnosis, and Management, Ginsberg, M. et al (eds), pp. 193-204. Blackwell, Malden. [Pg.64]

Bertsch, T., Mielke, O., Holy, S., Zimmer, W., Casarin, W., Aufenanger, J., Walter, S., Muehlhauser, R, Kuehl, S., Ragoschke, A., and Fassbender, K. 2001. Homocysteine in cerebrovascular disease an independent risk factor for subcortical vascular encephalopathy. Qin Chem Lab Med 39 721-724. [Pg.362]

Patyar S, Prakash A, Modi M, Medhi B (2011) Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep 63 618-628... [Pg.1364]

Detre JA, Alsop DC, Vives LR, Maccotta L, Teener JW and Raps EC (1988). Noninvasive MRI evaluation of cerebral blood flow in cerebrovascular disease. Neurology 50 633-641. [Pg.211]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...